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Abstract 
The M2 protein of influenza virus is an integral membrane protein with ion channel activity. This protein has been expressed in E. coli cells in 
an inducible manner. Expression of the M2 protein causes rapid lysis of BL2l@E3) pLysS E. coli cells upon induction with IFTG. M2 protein 
increases membrane permeability to a number of hydrophylic molecules, such as ONPG, uridine or impermeant translation inhibitors. The behaviour 
of M2 in bacteria resembles that of other viral proteins, such as poliovirus 3A and Semliki Forest virus 6K. 
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1. Introduction 
Influenza A virus is a negative-sense, single-stranded 
RNA virus with a genome fragmented into eight differ- 
ent pieces that encode at least 10 proteins (13). M2 pro- 
tein is synthesized from a spliced mRNA derived from 
genome RNA segment 7 [17]. Once synthesized, M2 be- 
comes membrane associated and is present in abundance 
on the surface of infected cells, although only a few 
molecules are incorporated into virions [ 11,3 11. M2 is an 
integral membrane protein that contains an extracellular 
domain consisting of approximately 24 N-terminal 
amino acids, a 19 residue trans-membrane domain and 
a cytoplasmic domain of 54 C-terminal amino acids [32]. 
The native form of the M2 protein is a homotetramer 
consisting of either a pair of disulfide-linked dimers or 
four disulfide-linked monomers [10,271. The protein is 
acylated, as occurs with other integral membrane pro- 
teins and is phosphorylated [10,26,28]. Despite the pres- 
ence of a potential glycosylation site, M2 is not glycosyl- 
ated. 
M2 protein localizes to the Golgi apparatus of influ- 
enza virus-infected cells and is transported to the cell 
surface by a pathway similar to that of other integral 
membrane proteins [32]. Some clues on the role of M2 
in the influenza virus replication cycle come from studies 
on the mechanism of action of the antiviral compound 
amantadine [23] since M2 protein is the target of inhibi- 
tion by amantadine hydrochloride [9]. Characterization 
of amantadine-resistant mutants of influenza virus has 
indicated that the resistance trait is located within the 
membrane-spanning domain of M2 [9]. However, the 
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precise mechanism of the antiviral activity of amantadine 
remains unclear. It seems that amantadine blocks influ- 
enza virus at two different steps of its growth cycle. Early 
during virus entry, the drug acts by inhibiting endosomal 
acidification and at a later stage of virus infection, by 
preventing virus release [12,21,23]. It has been claimed 
that amantadine induces a premature conformational 
change in HA that occurs in the trans-Golgi complex 
during the transport of HA to cell surface [25]. This 
premature conformational change in HA is though to be 
detrimental to the release of virus particles [21]. 
Membrane permeability is enhanced by influenza 
virus infection, leading to an imbalance of ions in the 
cytoplasm [4,18]. Expression of M2 in Xenopus oocytes 
increases membrane permeability to monovalent ions 
[20,29], suggesting that M2 is endowed with ion channel 
activity. Since M2 is able to oligomerize [10,27], it seems 
plausible that the oligomers located at the cell surface 
form hydrophylic pores, as with phage lytic proteins [30]. 
The present work shows that influenza M2 protein is 
able to increase membrane permeability when it is induc- 
ibly expressed in E. coli cells. These results resemble 
those reported with other viroporins, such as poliovirus 
3A or the Semliki Forest virus 6K protein [6,14,22]. 
2. Materials and methods 
2.1. Construction of M2 expression plasmid 
Construction of the vectors containing the M2 sequence was carried 
out by standard cloning procedures [19]. The M2 cDNA was kindly 
provided by Dr. R. Lamb (Howard Hughes Medical Institute, Illinois) 
and was cloned at the BamHI site of pGEM3. Two oligonucleotides 
were synthesized to amplify the M2 gene by polymerase chain reaction 
to create two unique NdeI and BumHI restriction sites, while also 
adding an additional translation stop codon. After amplification, the 
products were digested with the appropriate enzymes (BamHI and 
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NdeI) and ligated to the pET3 vector containing a T7 promoter, signals 
for efficient translation in E. coli and a transcription termination se- 
quence from bacteriophage T7 [15,24]. After transformation of DH5 
cells and restriction enzyme analysis of plasmid PET-M2, the region of 
pET3 encoding M2 was sequenced by the dideoxy method. Plasmid 
PET-M2 was then used to transform BL21(DE3) E. coli cells or 
BL21(DE3) pLysS E. coli cells. Plasmid pETll-M2 was generated by 
insertion of the M2 fragment obtained by iWeI/BamHI digestion of 
pET3-M2. 
2.2. Growth and induction of recombinant bacteria 
Single clones of BL21(DE3) cells or BL21@E3) pLysS cells contain- 
ing the indicated plasmid, were grown overnight at 37’C in LB medium 
in the presence of 100 pug/ml ampicillin and 34 pug/ml chloramphenicol 
in the case of pLysS cells. The cells were then diluted lOO-fold in M9 
medium supplemented with 0.2% glucose and antibiotics. When the 
culture reached 0.5-0.6 A, the cells were induced by addition of 1 mM 
IP’TG. Rifampicin (Sigma) was used, when indicated, at 150 &ml to 
inhibit transcription by E. coli RNA polymerase. 
2.3. Labelling and analysis of bacterial proteins 
To label the proteins synthesized by recombinant bacteria, 1 ml 
aliquots of bacteria cultures were collected and incubated with 2pCilml 
[“Slmethionine (1.45 Ci/mmol, Amersham) for 10 min at 37°C. The 
labelled bacteria were centrifuged for 1 min at 12,000 rpm in an Eppen- 
dorfmicrofuge and dissolved in lysis buffer (1% SDS, 17% glycerol, 100 
mM dithiothreitol, 0.37 M Tris-HCl (pH 6.8) and 0.024% Bromophenol 
blue). After SDS-PAGE, fluorography was carried out with 1 M sali- 
cylic acid for 1 h, and after drying, the gels were exposed to XAR films 
(Kodak) at -70°C. 
2.4. Uridine release from preloaded E. coli cultures. 
Cells were grown as described before and, 60 min before induction 
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(when A- reaches approx. 0.2-0.3), were loaded with 4 fiCi/ml 
PHluridine (27.3 Cilmmol. Amersham) for 1 h. After loadine. the cells 
berk pelleted and washed’twice with uridine-free pre-warm&l growth 
medium. Cells were then resuspended in the initial volume of growth 
medium and incubated at 37°C for 15 min. The cells were induced to 
express the target protein by addition of 1 mM IPTG. At the times 
indicated 0.2 ml aliquots of culture were centrifuged. Scintillation liquid 
(formula 989, Du Pont-New England Nuclear) was added to the super- 
natant to estimate radioactivity. 
2.5. P-galactosidase assays 
1 ml of bacteria culture was taken at different times after induction 
and the cells were centrifuged for 1 min at 12,000 rpm in an Eppendorf 
microfuge. To measure xtracellmar /?-galactosidase, 0.2 ml of 12 mM 
o-nitrophenyl-p-n-galactopyranoside (ONPG) was added to the super- 
natant. Reactions were carried out for 10 min at 30°C and stopped by 
addition of 0.4 ml 1 M sodium carbonate. A, was estimated to monitor 
the formation of the cleaved product. The pellet was used to measure 
the entry of ONPG into bacterial cells after resuspension in 1 ml of 
growth medium and mixing with 0.2 ml of 12 mM ONPG. Incubation 
was performed as indicated above, then cells were centrifuged to avoid 
interference due to the scattering of light by intact cells, and A,, was 
measured. To assay the total amount ofp-galactosidase present in cells, 
1 ml of growth culture was taken and 1 ml toluene was added to the 
medium. Addition of ONPG and further steps were performed as indi- 
cated above. 
2.6. Entry of hygromycin B
Bacteria were grown as described above. At the indicated times after 
induction with IPTG, 1 ml of culture was taken and 1 mM hygromycin 
B and 2 ~Cilml [35S]methionine w re added to the medium. Cells were 
incubated for 10 min at 37’C, bacteria were centrifuged and the pro- 
teins analyzed by SDS-PAGE as indicated. 
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Fig. 1. Induction of influenza virus M2 protein in E. coli cells. BL21 (DE3) pLysS cells containing pET3-M2 plasmid or BL21@E3) cells containing 
pET1 l-M2 plasmid were grown and induced with 1 mM IPTG as described in section 2. At the indicated times post-induction proteins were labelled 
with [35S]methionine and then analyzed by SDS-PAGE. Where indicated, 150 pg/ml rifampicin were added to the cultures 30 min after addition of 
IPTG. The position of M2 protein is indicated. 
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Fig. 2. Growth curve of BL21(DE3) pLysS cells and BL2I(DE3) cells expressing M2 protein. E. coli cells were grown as indicated in section 2. At 
zero time, cells were induced with 1 mM IPTG and cell density (~4~ 3 was measured at the indicated times. Panel A: pET3 (0), pET3-M2 (O), 
pET3-M2 plus IPTG {A), pET3-MZ plus IPTG plus ~f~pi~in (D) in BL2l~E3) pLysS cells. Panel B: pETI (0), pET1 l-M2 (e); pET1 I-M2 plus 
kTG &);-pET11-M27plus IPTG plus rifampicin (4) in BL21(DE3) cells. 
3. Results 
3.1. ~l~~~~g and expression of j~~~enzu vir~ A42 protein 
in E. coli cells 
The M2 influenza virus protein was cloned in pET 
plasmids. The inducible expression of the protein was 
achieved using two different systems [24]. Either the pro- 
tein was cloned under the control of gene # 10 promoter 
of T7 bacte~ophage (pET3 plasmid) generating the 
pET3-M2 plasmid or under the control of a UT7 hy- 
brid promoter containing a Zuc operator before the M2 
gene @ET1 1 plasmid) generating the pETll-M2 plas- 
mid. These constructs were transformed into BL21(DE3) 
E. cofi cells which contain the integrated T7 RNA polym- 
erase gene under the lac UY5 promoter. BL21(DE3) 
pLysS E. coZi cells were also used; these cells are lysogens 
which express the T7 phage lysozyme, a natural inhibitor 
of the T7 RNA polymerase, at low levels [24]. We have 
used this system successfully to express toxic proteins 
from animal viruses ]1416,22]. 
Addition of IPTG to BL21(DE3) pLysS cells contain- 
ing pET3-M2 plasmid induces the expression of a pol- 
ypeptide migrating on SDS-PAGE with the mobility ex- 
pected for influenza M2 protein. This is the only protein 
that is synthesized in the presence of rifampicin which 
blocks transcription by E. c&i RNA polymerase but not 
by T7 polymerase (Fig. 1A). Expression of the influenza 
M2 protein in the presence of lysozyme is very toxic since 
synthesis of M2 protein could not be detected after 9& 
120 min post-induction. However, synthesis of M2 from 
pET1 l-M2 plasmid in BL21@E3) ceils devoid of phage 
T7 lysozyme, takes place to higher levels and synthesis 
of M2 was detected after longer post-induction times 
(Fig. 1B). 
3.2. Expression of A42 protein induces cell fysis 
To measure cell lysis upon M2 expression, the AsG0 of 
cultures was determined at various times after induction 
of cells bearing plasmid pET3-M2 or pET1 l-M2 (Fig. 2). 
A drastic fall in cell density at 60 min after IPTG induc- 
tion is observed in the pET3-M2 plasmi~L2l(DE3) 
pLysS cell system in the presence or absence of ri- 
fampicin (Fig. 2A). This lytic effect could be a conse- 
quence of membrane permeability alterations allowing 
the leakage of T7 lysozyme from the cytoplasm to the 
periplasmic space, where its lytic activity would be ex- 
erted. 
The expression of M2 protein in BL21(DE3) cells 
which do not contain lysozyme was slightly toxic after 
longer post-induction times (Fig. 2B). Lysis in this case, 
was observed upon induction with IPTG plus rifampicin, 
but not with IPTG alone, suggesting that in~bition of 
E. cofi gene expression helps the lytic capacity of influ- 
enza M2 protein. This result indicated that high levels of 
M2 expression for a long period of time is toxic for 
bacteria, as occurred with the synthesis of poliovirus 3A 
protein, or SFV 6K protein [6,14,15,22]. 
3.3. Modijication of E. coli membrane permeab~f~ty by the 
expression of the M2 protein 
To analyze permeability changes in response to influ- 
enza virus M2 protein, different assays were performed. 
We first tested the leakage of radioactivity from [3H]urid- 
ine-preloaded cells. The release of ]3FQuidine was moni- 
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tored after induction of M2 synthesis (Fig. 3A). Substan- 
tial amounts of radioactivity are released to the medium 
and are detected soon a.fter induction of M2 synthesis. 
As a control, bacteria bearing pET3 plasmid, induced in 
parallel do not show that behaviour. 
Modifications in membrane permeability by a number 
of agents is usually observed in both directions (influx 
and et&x) [5]. Thus, not only the release of ions or small 
metabolites from the cell interior to the medium takes 
place, but also compounds normally readily excluded 
enter into cells [5]. Hence, the entry of ONPG into the 
cytoplasm was measured during the synthesis of M2. 
Induction of M2 expression caused an increased ONPG 
entry into bacteria as compared with control cells carry- 
ing the parental plasmid and treated with IPTG (Fig. 
3B). No difference in the total amount of /3-galactosidase 
activity between the two clones was found (Fig. 3C). 
Moreover, induction of M2 expression gives rise to in- 
creased /I-galactosidase activity in the extracellular me- 
dium after 60 min post-induction (Fig. 3B), probably as 
a consequence of cell lysis. 
Some translation inhibitors do not pass the membrane 
barrier of intact cells, but these compounds readily cross 
the cellular membrane after modification by membrane 
active agents or viral infection [2,3,5]. Hygromycin B has 
been one of the most non-permeant inhibitors used, in 
such a way that inhibition of protein synthesis by this 
antibiotic constitutes a very sensitive test to assay modifi- 
cations of membrane permeability in intact cells [7,8]. 
The previous experiments were performed in the pET3- 
M2/BL21(DE3) pLysS system. Because the BL21(DE3) 
pLysS cells lysed rapidly upon M2 expression, we used 
both systems: pET3-M2/BL2 1 (DE3)pLysS and pET1 1 - 
M2/BL21 (DE3) to assay the entry of hygromycin B. Fig. 
4 shows that hygromycin B does not inhibit protein syn- 
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thesis in control cells containing pET3 or pETl1 vectors, 
whereas protein synthesis was powerfully blocked in the 
recombinant clones that express M2. Thus, the expres- 
sion of M2 protein gives rise to a strong and rapid mod- 
ification in membrane permeability, even at early times 
(30 min) post-induction, when cell lysis is not detected 
even in pLysS cells. Therefore, these results lead us to the 
conclusion that M2 permeabilizes E. coli cells to a num- 
ber of compounds non-specifically. 
4. Discussion 
During the process of animal virus infection, an in- 
crease in membrane permeability takes place [5,6j. Late 
in infection, the lipidic barrier constituted by the plasma 
membrane is destroyed and cell lysis ensues. Although 
the phenomenology of these changes is fairly well 
known, the viral proteins involved in these modifications 
remain poorly characterized [5,6]. 
Recent findings suggest a role for poliovirus 3A pro- 
tein and togavirus 6K protein in the modification of 
membrane permeability of infected cells [6,14,22]. Both 
proteins share similarities in their hydrophobic profiles 
and both contain a hydrophobic region at the carboxy 
terminus that can form an amphipathic helix [6,6,32]. A 
similar structure is also found in influenza M2 protein 
[6]. It has been speculated that late during influenza virus 
infection, M2 protein would regulate the pH within the 
Golgi apparatus to facilitate transport of the native acid- 
sensitive HA to the plasma membrane of infected cells, 
a process necessary for the release of virus particles [25]. 
Influenza virus induces membrane leakiness in the in- 
fected cells [4,18], but the relationship between the ex- 
pression of any influenza protein, including M2, and 
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Fig. 3. Permeability changes in BL21(DE3) pLysS cells after induction of M2 expression. Panel A: BL21(DE3) pLysS cells containing pET3 (0) or 
pET3-M2 plasmids (0) were preloaded for 1 h with 4&i/ml [‘H@ridine and at zero time were induced with 1 mM IPTG. At the times post-induction 
indicated the level of radioactivity in the culture medium was measured. Panel B: BL21(DE3) pLysS cells containing pET3 (open symbols) or pET3-M2 
(closed symbols) plasmids were induced with 1 mM IPTG at zero time. At the indicated times the entry of ONPG (O/O) or /I-galactosidase activity 
recovered from the extracellular medium (Wn) was analyzed. Measurements are given as A+,,, nm. Panel C: total amount of /I-galactosidase activity 
in cells containing pET3(n) or pET3-M2 (A). 
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Fig. 4. Effect of hygromycin B on protein synthesis in cells expressing 
the influenza virus M2 protein. Cells were grown and induced as indi- 
cated in section 2. Half an hour after IPTG induction, proteins were 
labelled by addition of [r’S]methionine for 10 min at 37°C. 1 mM 
hygromycin B was present during the labelling period. Cells were then 
centrifuged and the proteins analyzed by SDS-PAGE. Panel A: pET3 
or pET3M2 plasmids/BL21@E3) pLysS cells. Panel B: pETllGT 
pET1 l-M2 plasmid/BL21(DE3) cells. 
membrane modifications in mammalian cells has not 
been analyzed yet. The lytic potential of M2 protein in 
E. coli and its behaviour as an ion-channel, when ex- 
pressed in Xenopus oocytes [20] makes M2 a good candi- 
date for the protein involved in modifying membrane 
permeability in influenza virus-infected cells. However, 
further analyses on the mode of action of M2 in mam- 
malian cells is still necessary to reach this conclusion. 
Our present results together with previous findings on 
poliovirus 3A and togavirus 6K proteins lend support to 
the concept that animal viruses encode specific proteins, 
the viroporins, involved in modifying membrane perme- 
ability and causing cell lysis by forming pores in the 
plasma membrane [1,3]. A relationship between the role 
of M2 in inducing permeability changes and the budding 
or release of virus particles can be envisaged. Finally, the 
efficient expression of M2 in the bacterial system de- 
scribed in this work should facilitate future research on 
the mode of action of M2 and its interaction with the 
antiviral compound amantadine. 
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